Evidence map›Paper›PMID 39796706›Full record

ArticleCancers2024

Differential Effects of GLP-1 Receptor Agonists on Cancer Risk in Obesity: A Nationwide Analysis of 1.1 Million Patients.

Shauna Levy, Abdallah Attia, Rami M Elshazli, Ahmed Abdelmaksoud, Danielle Tatum, Hani Aiash, Eman A Toraih

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Metabolic Modulation in Cancer Care: The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Review
  7. Article
  8. Review
  9. Article
  10. Exposure to GLP-1RA and Risk of Structural Progression in Differentiated Thyroid Cancer.The Journal of clinical endocrinology and metabolism · 2026
    Observational
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shauna LevyDepartment of Surgery, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Abdallah AttiaDepartment of Surgery, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Rami M ElshazliDepartment of Surgery, Tulane University School of Medicine, New Orleans, LA 70112, USA.ORCID 0000-0002-3381-2641
Ahmed AbdelmaksoudDepartment of Internal Medicine, University of California, Riverside, CA 92521, USA.
Danielle TatumDepartment of Surgery, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Hani AiashDepartment of cardiovascular perfusion, Upstate Medical University, Syracuse, NY 13210, USA.
Eman A ToraihDepartment of Surgery, Tulane University School of Medicine, New Orleans, LA 70112, USA.ORCID 0000-0001-9267-3787

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cancer-risk reductiondulaglutideliraglutidepersonalized medicinesemaglutide

Identifiers

PMID39796706
PMCPMC11720624

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.